English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.

Drysdale, Kathryn, Ntuli, Yevedzo, Bestwick, Jonathan, Gelson, William, Agarwal, Kosh, Forton, Daniel, Mutimer, David, Elsharkawy, Ahmed M, Townley, Ceri, Mahomed, Faizel and Foster, Graham R (2020) English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Alimentary pharmacology & therapeutics. ISSN 1365-2036. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://onlinelibrary.wiley.com/journal/13652036

Abstract

BACKGROUND

In England, choice of hepatitis C therapy is determined by national contracts that change with time, facilitating comparisons between different regimens. England has a diverse population with hepatitis C including large proportions of uncommon viral genotypes.

AIM

To evaluate efficacy of directly acting anti-viral treatments for hepatitis C in England using real-world data from the national treatment registry.

METHODS

Sustained virological response (SVR) rates 12 weeks after treatment completion for patients treated between 2014 and August 2018 who attended for SVR tests were analysed in univariate subgroups using Chi-squared tests. Multivariate models were constructed with clinically relevant variables to determine predictors of SVR and evaluate the impact of treatment regimens.

RESULTS

SVR data were available on 14,603 treated patients. The overall SVR rate was 95.59% [95% CI 95.25%-95.91%]. Multivariable regression modelling in patients with genotype 1 infection showed that the odds of SVR with elbasvir/grazoprevir were higher than for those treated with sofosbuvir/ledipasvir (OR 1.891, 95% CI 1.072-3.336, P = 0.028). For genotype 3, we found no significant difference between any of the treatment regimens. Patients who completed at least one third of the planned treatment duration achieved SVR rates in excess of 80%.

CONCLUSIONS

All of the currently licensed hepatitis C direct-acting anti-viral regimens had similar efficacy (>95%) in an unselected population. Noncompletion of planned treatment duration still resulted in over 80% SVR rates provided that more than one third of treatment was completed.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: WC Communicabable diseases
WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Related URLs:
Depositing User: Jamie Edgar
Date Deposited: 04 Jun 2020 10:30
Last Modified: 04 Jun 2020 10:30
URI: http://www.repository.uhblibrary.co.uk/id/eprint/3135

Actions (login required)

View Item View Item